We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 11, 2020

Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained With 8-Week Dose Interruption

Journal of Investigative Dermatology

 

Additional Info

Journal of Investigative Dermatology
Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained With 8-Week Dose Interruptions: A Model-Based Evaluation
J Invest Dermatol 2020 Sep 22;[EPub Ahead of Print], P Chanu, L Musib, X Wang, S Cheeti, S Girish, R Bruno, T Lu, J Reddy, JY Jin, I Caro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading